文献速递肺栓塞与肺血管病

肺动脉高压与慢性血栓栓塞性肺动脉高压中的肾功能不全与结局:个体参与者数据荟萃分析

Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis.
PubMed 文献 · Eur Respir J · 2025-08-08

该个体参与者数据荟萃分析纳入18项Ⅲ期随机临床试验的6694例肺动脉高压患者,评估肾功能不全的患病率及其与血流动力学和预后的关系。结果显示13.5%的患者基线eGFR<60 mL·min-1·1.73 m-2,较低eGFR与较高平均右心房压和较低心脏指数相关,且与全因死亡风险增加独立相关;肺动脉高压治疗仅带来小幅eGFR改善。

要点

  • PAH和CTEPH患者中肾功能不全常见,基线eGFR<60者占13.5%。
  • 较低基线eGFR与 worse 血流动力学(高mRAP、低心脏指数)及全因死亡风险增加相关。
  • 肺动脉高压治疗对eGFR的改善幅度很小。

核心结论

  • 在PAH和CTEPH患者中,肾功能不全高度流行,与更差的血流动力学和临床结局相关。
  • 在该肾功能相对保留的队列中,肺动脉高压治疗仅带来极小的eGFR改善。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入18项肺动脉高压治疗的Ⅲ期随机临床试验,共6694例参与者。
  • 使用2021年CKD-EPI(不含种族)公式计算eGFR。

主要发现

  • 平均年龄49.6±15.5岁,女性占78%,特发性PAH占58%。
  • 907例(13.5%)参与者基线eGFR<60 mL·min-1·1.73 m-2。
  • 较低基线eGFR与较高平均右心房压和较低心脏指数相关。
  • 12-16周时,mRAP较基线下降10 mmHg或心脏指数增加1 L·min-1·m-2,分别仅与eGFR增加1.7 mL·min-1·1.73 m-2(95%CI -2.9至-0.5;p=0.006)或1.4 mL·min-1·1.73 m-2(95%CI 0.5至2.4;p=0.003)相关。
  • 基线eGFR每低10 mL·min-1·1.73 m-2,全因死亡风险增加(校正HR 1.16,95%CI 1.08-1.23;p<0.001)。

临床怎么用

  • 在PAH和CTEPH管理中应关注肾功能,基线eGFR较低提示血流动力学更差和死亡风险更高。
  • 不应期望肺动脉高压治疗能大幅改善肾功能,需综合管理肾功能不全。

局限性

  • 研究队列肾功能相对保留,可能限制对严重肾功能不全患者的推广。
  • 为临床试验数据的事后分析,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) cause right ventricular dysfunction with extrapulmonary sequelae including renal dysfunction. We sought to characterise renal dysfunction in PAH and CTEPH and to assess the effect of pulmonary hypertension treatment on renal function. METHODS: We performed an individual participant data meta-analysis of 6694 participants from 18 phase III randomised clinical trials of pulmonary hypertension therapies. We calculated estimated glomerular filtration rate (eGFR) using the race-agnostic 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. RESULTS: The mean±sd age was 49.6±15.5 years, 78% were female and 58% had idiopathic PAH. A total of 907 (13.5%) participants had a baseline eGFR <60 mL·min-1·1.73 m-2. Lower baseline eGFR correlated with higher mean right atrial pressure (mRAP) and lower cardiac index. At 12-16 weeks, a 10 mmHg decrease in mRAP from baseline or a 1 L·min-1·m-2 increase in cardiac index was associated with only a 1.7 mL·min-1·1.73 m-2 (95% CI -2.9--0.5 mL·min-1·1.73 m-2; p=0.006) or a 1.4 mL·min-1·1.73 m-2 (95% CI 0.5-2.4 mL·min-1·1.73 m-2; p=0.003) increase in eGFR, respectively. A 10 mL·min-1·1.73 m-2 lower baseline eGFR was associated with an increased risk of all-cause mortality (adjusted hazard ratio 1.16, 95% CI 1.08-1.23; p<0.001). Interestingly, pulmonary hypertension treatment was associated with only a small improvement in eGFR at 12-16 weeks (adjusted β 2.0 mL·min-1·1.73 m-2, 95% CI 1.4-2.6 mL·min-1·1.73 m-2; p<0.001). CONCLUSION: Renal dysfunction remains highly prevalent in PAH and CTEPH and is associated with worse haemodynamics and worse clinical outcomes. In this cohort with relatively preserved renal function, pulmonary hypertension treatment was associated with only a minimal improvement in eGFR.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Meservey A, Al-Naamani N, Minhas J, et al. Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis. Eur Respir J. 2025. PMID: 40404217. doi:10.1183/13993003.02400-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。